Adaptive Biotechnologies Corporation $ADPT Shares Sold by Catalio Capital Management LP

Catalio Capital Management LP lessened its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 7.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 821,195 shares of the company’s stock after selling 63,695 shares during the period. Adaptive Biotechnologies makes up 2.5% of Catalio Capital Management LP’s investment portfolio, making the stock its 16th largest position. Catalio Capital Management LP’s holdings in Adaptive Biotechnologies were worth $13,336,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ADPT. AQR Capital Management LLC lifted its stake in shares of Adaptive Biotechnologies by 45.8% in the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after purchasing an additional 97,444 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after purchasing an additional 2,914 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of Adaptive Biotechnologies in the 1st quarter valued at $93,000. New York State Common Retirement Fund lifted its stake in shares of Adaptive Biotechnologies by 39.2% in the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after purchasing an additional 13,300 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Adaptive Biotechnologies by 728.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after purchasing an additional 333,379 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Negative Sentiment: Adaptive Biotechnologies priced an upsized $300 million offering of 0% convertible senior notes due 2031, which raises fresh capital but also signals potential dilution risk and added complexity for shareholders. The company plans to use the proceeds to repay the OrbiMed Purchase Agreement, fund capped call transactions, and repurchase $25 million of stock to help offset dilution. Article Title
• Negative Sentiment: Multiple insider sales were disclosed, including Chief Scientific Officer Harlan S. Robins selling 100,000 shares and another 6,160 shares under a 10b5-1 plan. While pre-planned, the volume of insider selling may reinforce caution around the stock. Article Title
• Neutral Sentiment: BTIG Research reaffirmed its Buy rating and kept a $22 price target, suggesting analysts still see meaningful upside from current levels. Article Title
• Neutral Sentiment: The company’s recent earnings trend remains supportive, with Q1 revenue up 35.1% year over year and results beating expectations, which helps offset some of the financing-related concerns.

Adaptive Biotechnologies Trading Down 2.6%

ADPT opened at $16.78 on Thursday. The stock’s 50-day moving average price is $14.72 and its 200 day moving average price is $15.59. Adaptive Biotechnologies Corporation has a 12-month low of $9.96 and a 12-month high of $20.76. The firm has a market cap of $2.69 billion, a price-to-earnings ratio of -50.85 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same quarter in the prior year, the business earned ($0.20) EPS. Adaptive Biotechnologies’s revenue was up 35.1% on a year-over-year basis. On average, research analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CFO Kyle Piskel sold 3,115 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $13.04, for a total transaction of $40,619.60. Following the sale, the chief financial officer owned 256,725 shares in the company, valued at $3,347,694. This represents a 1.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Francis Lo sold 39,741 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $17.49, for a total value of $695,070.09. Following the sale, the insider owned 250,934 shares in the company, valued at approximately $4,388,835.66. This trade represents a 13.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 589,694 shares of company stock worth $8,945,827 over the last quarter. 5.70% of the stock is currently owned by insiders.

Analyst Ratings Changes

ADPT has been the topic of several research reports. Guggenheim reissued a “buy” rating and set a $21.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. JPMorgan Chase & Co. decreased their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Morgan Stanley decreased their target price on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. BTIG Research reissued a “buy” rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday. Finally, Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $20.33.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.